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Human immunodeficiency virus type 1 (HIV-1) along with simian immunodeficiency viruses from chimpanzees (SIVcpz) and three
species of Old World monkeys from the genus Cercopithecus have been shown to encode a Vpu protein. To date, the functional
characterization of Vpu has been limited to a small number of subtype B and more recently subtype C Vpu proteins. Using a recently
developed VpuEGFP reporter system, we have shown that the subtype B and C Vpus are capable of preventing CD4 from being expressed on
the cell surface. Using the same reporter system, we report here on the expression and functional analysis of Vpu protein from four SIVcpz
isolates (CAM13, ANT, TAN1, and GAB1). All four SIV Vpu fusion proteins were efficiently expressed and prevented CD4 expression on
the cell surface and induced CD4 degradation. This was surprising as three of the SIVcpz Vpu fusion proteins had only one canonical casein
kinase II (CK-II) site (CAM13, ANT, TAN1) while previous studies with laboratory adapted HXB2 had indicated that both CK-II sites were
required for CD4 degradation. Both ANT and TAN1 Vpu sequences encoded five consecutive negatively charged amino acids residues
following the only CKII site (SAIEEDEE for ANT; SGVEEDEE for TAN1). We thus explored the possibility that this stretch of negatively
charged amino acids might substitute for the lack of second CK-II site. Substitution of the aspartic acid at position 61 and glutamic acid at
position 63 in the SIVcpz ANT Vpu within with lysine residues abolished the ability of this protein to down-modulate cell surface expression
of CD4. Similarly, change of a serine to an alanine residue following the single consensus CK-II site of the CAM13 Vpu (SGNESDGGEEE)
abolished CD4-down-regulation, suggesting that this serine was phosphorylated in the absence of a canonical CK-II site. Our results indicate
that the serine was required, suggesting that this serine was phosphorylated by CK-II or possibly another cellular kinase. Taken together,
these results show for the first time that Vpu proteins from SIVcpz isolates, although quite diverse in sequence and predicted secondary
structure from the HIV-1 subtype B protein, are capable of down-regulating CD4, which is one of the major functions of the HIV-1 protein.
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Both authors contributed equally to this work.envelope glycoprotein precursor (Hout et al., 2004; Schwartz
et al., 1990). Studies on the Vpu protein from HIV-1 subtype
B isolates have shown that Vpu is localized predominantly to
the Golgi complex and has two important functions within the
virus infected cell (Kimura et al., 1994; Pacyniak et al., 2005;
Strebel et al., 1989). One is the enhancement of virion release
from infected cells, which has been associated with the
transmembrane domain (Bour et al., 1995; Klimkait et al.,
1990; Schubert et al., 1996a, 1996b). The second function of005) 46 – 60
L.M. Gomez et al. / Virology 335 (2005) 46–60 47the Vpu protein is the down-modulation of CD4, which is
believed to reside within the cytoplasmic domain of the
protein (Willey et al., 1992; Vincent et al., 1993). Both of the
predicted alpha-helical domains, the transmembrane domain,
and the phosphorylation of the serine residues within the
casein kinase II sites of the cytoplasmic domain have been
shown to be essential to the CD4 down-regulation property of
Vpu (Paul and Jabbar, 1997; Tiganos et al., 1998). In addition
to cell culture studies, the Vpu protein is also a determinant of
in vivo primate lentiviral pathogenicity. Using the simian-
human immunodeficiency virus (SHIV)/macaque model, we
have shown that an intact Vpu contributes to the rapid loss of
circulating CD4+ T cells in macaques infected with these
pathogenic SHIVs (McCormick-Davis et al., 1998; Singh et
al., 2001, 2003; Stephens et al., 2002).
Although the majority of the simian immunodeficiency
viruses (SIV) lack a vpu gene, this gene is also encoded by
SIVs naturally infecting chimpanzees (SIVcpz), greater spot-
nosed monkeys (SIVgsn), mona monkeys (SIVmon), and
mustached monkeys (SIVmus) (Barlow et al., 2003; Courg-
naud et al., 2002, 2003; Santiago et al., 2002). However, the
predicted amino acid sequence of the Vpu proteins from
these various SIVs, including SIVcpz strains from central
(Pan troglodytes troglodytes) and eastern (Pan troglodytes
schweinfurthii) chimpanzees, while retaining one or more
consensus casein kinase II motifs in the cytoplasmic
domain, are highly divergent from each other as well as
from HIV-1 group M Vpu sequences. Thus, it remainsFig. 1. The sequence and predicted secondary structure of the Vpu proteins analyze
to the left of the sequences. Those residues bolded and in italics represent th
SIVcpzCAM13 sequences with a diamond above them correspond to residues thaunknown whether these structural homologues of the HIV-1
Vpu have the same functions (CD4 down-modulation and
enhancement of virion release).
Recently, we developed a reporter system that permits
analysis of intracellular transport and CD4 down-regulation
by Vpu (Pacyniak et al., 2005; Singh et al., 2003). In this
study, we have used this reporter system to analyze the
intracellular transport and CD4 down-regulating function of
four SIVcpzVpu proteins.We show that despite their sequence
divergence from each other as well as HIV-1 groupM, N, and
O isolates, these four SIVcpz Vpu proteins were capable of
down-modulating cell surface expression of human CD4.Results
Predicted secondary structure and phylogenetic analysis of
HIV-1 and the SIVcpz Vpu proteins
The secondary structure of the SIVcpz Vpu proteins were
compared to the well-studied subtype B Vpu protein. As
shown in Fig. 1, the subtype B and C Vpu proteins as well
as all four of the SIVcpz Vpu proteins had a predicted
transmembrane domain at the N-terminus of the protein. As
previously reported, the cytoplasmic domain subtype B Vpu
protein had a predicted secondary structure which consisted
of two a-helical regions that were separated by a random
coil region (Schubert and Strebel, 1994; Schubert et al.,d in this study. Sequence of the Vpu proteins analyzed with the isolate name
e potential casein kinase II sites. The residues of the SIVcpz ANT and
t were altered by site-directed mutagenesis as described in the text.
Fig. 2. Phylogenetic tree depicting the relationship of HIV-1 and SIVcpz
strains in the vif-vpr-vpu region of their genome. SIVcpz strains from P. t.
troglodytes are shown in red, while those from P. t. schweinfurthii are
shown in blue; strains which gave rise to the vpu genes analyzed in this
study are boxed. Concatenated Vif-Vpr-Vpu amino acid sequences (370
consensus length) of SIVcpzCAM13 (GenBank accession number
AY169968), SIVcpzGAB1 (X52154), SIVcpzTAN1 (AF447763), and SIVcpz
ANT (U42720) were compared to the corresponding sequences in
SIVcpzUS (AF103818), SIVcpzCAM3 (AF115393), SIVcpzCAM5
(AJ271369); HIV-1 group N strain YBF30 (AJ006022), group O strains
ANT70 (L20587) and MVP5180 (L20571), and group M subtypes B (strain
HXB2; K03455) and C (96BW16B01; AF110976). Sequences were
aligned using Clustal W (Thompson), with minor manual adjustment.
Trees were estimated using the neighbor joining method (Saitou and Nei,
1987). Numbers denote branches with bootstrap values of at least 70%. The
scale bars indicate 0.2 replacements per site. Phylogenetic relationships of
the vpu genes analyzed in this study.
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and SIVcpzCAM13, had cytoplasmic domains with a similar
predicted secondary structure to the subtype B Vpu. The
two other SIVcpz Vpu proteins (TAN1 and ANT) had a
predicted secondary structure that was much different from
the subtype B Vpu. In addition to the predicted trans-
membrane domain from amino acids 11 to 31, the SIVcpz
TAN1 Vpu protein had one predicted a-helical region in the
predicted cytoplasmic domain from amino acid residues 32
to 54, which was followed by five consecutive negatively
amino acids. The SIVcpz ANT Vpu had a predicted
transmembrane domain from amino acids 5 to 27 and two
a-helical regions in the cytoplasmic domain from amino
acids 28 to 38 and 44 to 64, which was also followed by five
consecutive negatively amino acids. This is not surprising
given that the SIVcpzPtt strains are as closely related to each
other as they are to HIV-1 groups M and N, whereas the
SIVcpzPts strains are highly divergent from both HIV-1 and
SIVcpzPtt strains (Fig. 2). Thus, consistent with the
phylogenetic relationships of these viruses, the Vpu proteins
from SIVcpzPtt strains (CAM13 and GAB1) had secondary
structure that was similar to HIV-1 while the SIVcpzPts
strains exhibited structural features that were quite distinct.
Expression of the SIVcpz Vpu fusion proteins
We first transfected 293 cells with vectors expressing
either the subtype B VpuEGFP, the subtype C VpuSC
EGFP1, EGFP or each of the four SIVcpzEGFP constructs
followed by radiolabeling and immunoprecipitation of
EGFP containing proteins with an antibody against EGFP.
The results are shown in Fig. 3. Using an antiserum specific
for EGFP, EGFP-specific proteins were immunoprecipitated
from cells transfected with pcEGFP, pcvpuSCEGFP1, and
pcVpuEGFP having an Mr of 26,000, 34,000, and 43,000,
respectively (Pacyniak et al., 2005; Singh et al., 2003).
Immunoprecipitation of EGFP-specific proteins from 293
cells transfected with vectors expressing the four SIVcpz
Vpu fusion proteins revealed that the VpuTAN1EGFP and
VpuANTEGFP had an Mr of approximately 43,000 while the
VpuGAB1EGFP and VpuCAM13EGFP had an Mr of approx-
imately 32,000. These results indicate that despite the Vpu
proteins being approximately the same length (82 to 88
amino acids), the fusion proteins with EGFP had markedly
different Mr by SDS-PAGE. This finding is similar to what
we recently found in a recent study of subtype B and C Vpu
fusion proteins (Pacyniak et al., 2005).
The SIVcpz Vpu fusion proteins are associated with
membrane-enriched fractions
We determined if the four SIVcpz VpuEGFP chimeric
proteins were associated with the membrane fractions of the
cell. 293 cells were transfected with vectors expressing
EGFP, VpuEGFP, VpuSCEGFP1 or the four SIVcpzVpuEGFP
constructs. At 48 h, the cells were radiolabeled with 35S-methionine/cysteine, P100 and S100 fractions isolated, and
the EGFP containing proteins were immunoprecipitated from
each fraction using an anti-EGFP serum. As shown in Fig. 4,
transfection of cells with the vector expressing EGFP vector
resulted in the EGFP remaining in the S100 fraction (Lane 1).
In contrast, transfection of cells with the vectors expressing
VpuEGFP (Fig. 4, lane 4) the VpuSCEGFP1 (Fig. 3, Lane 6)
resulted in these proteins associated with the membrane-
enriched P100 fraction. Similar to 293 cells transfected with
vectors expressing VpuEGFP or VpuSCEGFP1, Vpu fusion
proteins were immunoprecipitated from P100 fractions
isolated from cells transfected with vectors expressing each
of the four SIVcpz Vpu constructs. These results suggest that
all four SIVcpz Vpu fusion proteins were associated with
membrane-enriched P100 fractions.
Fig. 3. ImmunoprecipitationofVpuEGFPfusionproteinsfrom293cells.Cells
were transfected with vectors expressing EGFP, VpuEGFP, VpuSCEGFP1, or
the fourSIVcpzVpuEGFPfusionproteins.At 48hpost-transfection, cellswere
starved for methionine/cysteine and then radiolabeled with 35S-methionine/
cysteine for 5h.EGFPcontainingproteinswere immunoprecipitated fromcell
lysates using a rabbit polyclonal antiserum to EGFP as described inMaterials
and methods. All samples were analyzed under reducing conditions by
SDS-PAGE (10% gel) and visualized by standard autoradiographic
techniques. Lane 1, EGFP containing proteins immunoprecipitated from
vector pcDNA3.1(+) transfected cells. Lane 2, EGFP containing proteins
immunoprecipitated from cells transfected with a vector expressing EGFP.
Lane 3, EGFP containing proteins immunoprecipitated from cells trans-
fected with a vector expressing VpuEGFP (subtype B Vpu fusion protein).
Lane 4, EGFP containing proteins immunoprecipitated from cells trans-
fected with a vector expressing VpuSCEGFP1 (subtype C Vpu fusion
protein). Lane 5, EGFP containing proteins immunoprecipitated from cells
transfected with a vector expressing VpuANTEGFP. Lane 6, EGFP-
containing proteins immunoprecipitated from cells transfected with a vector
expressing VpuTAN1EGFP. Lane 7, EGFP-containing proteins immunopre-
cipitated from cells transfected with a vector-expressing VpuCAM13EGFP.
Lane 8, EGFP-containing proteins immunoprecipitated from cells trans-
fected with a vector expressing VpuGAB1EGFP.
Fig. 4. The SIVcpzVpuEGFP fusion proteins are associated with membrane
enriched P100 fractions. 293 cells were transfected with vectors expressing
EGFP, VpuEGFP, VpuSCEGFP1, or the vectors expressing the SIVcpz
VpuEGFP fusion proteins. After 48 h, cells were starved for methionine/
cysteine and then radiolabeled with 35S-methionine/cysteine for 5 h. Cells
were then used to prepare S100 and P100 fractions as described in the text.
The odd numbered lanes are immunoprecipitation reactions of EGFP
proteins from S100 fractions, whereas the even-numbered lanes are
immunoprecipitation reactions of EGFP proteins from membrane-enriched
P100 fractions. Lanes 1 and 2, cells transfected with a vector expressing
EGFP. Lanes 3 and 4, cells transfected with a vector expressing VpuEGFP.
Lanes 5 and 6, cells transfected with a vector expressing VpuSCEGFP1.
Lanes 7 and 8, cells transfected with a vector expressing VpuANTEGFP.
Lanes 9 and 10, cells transfected with a vector expressing VpuTAN1EGFP.
Lanes 11 and 12, cells transfected with a vector expressing VpuCAM13EGFP.
Lanes 13 and 14, cells transfected with a vector expressing VpuGAB1EGFP.
Lanes 15 and 16, cells transfected with the pcDNA3.1 vector.
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We next examined the intracellular localization of the
four SIVcpz Vpu fusion proteins. Consistent with previous
results, transfection of vectors expressing EGFP and ECFP-
Golgi revealed a diffuse expression of EGFP consistent
with cytoplasmic expression of this protein (Figs. 5A–D).
Co-transfection of 293 cells with vectors expressing
VpuEGFP and DsRed-ER resulted in partial co-localization
(Figs. 5E–H) and co-transfection with vectors expressing
VpuEGFP and ECFP-Golgi resulted in a localization to the
Golgi complex (Figs. 5I–L), which is similar to our
previous observations (Pacyniak et al., 2005). In contrast,
co-transfection with vectors expressing VpuSCEGFP1 and
ECFP-Golgi resulted partial co-localization at an intra-
cellular location (Figs. 5M–P) while co-transfection with
vectors expressing VpuSCEGFP1 and ECFP-Mem resulted
in nearly complete co-localization, including expression at
the cell plasma membrane (Figs. 5Q–T). The results of the
co-transfection with vectors expressing VpuANTEGFP and
either DsRed-ER (Figs. 6A–D) or ECFP-Golgi (Figs. 6E–
H) resulted in partial co-localization with these markers
(Figs. 6A–H). In contrast, co-transfection with vectors
expression with VpuANTEGFP and ECFP-Mem resulted in
almost complete co-localization, including localization at
the cell plasma membrane (Figs. 6I–L). Similar resultswere obtained with the expression of VpuTAN1EGFP,
VpuCAM13EGFP, and VpuGAB1EGFP (data not shown).
These results indicate that the SIVcpz Vpu fusion proteins,
similar to the subtype C Vpu fusion protein, were trans-
ported to the cell surface.
CD4 down-regulation by the SIVcpz Vpu fusion proteins
The ability of the SIVcpz Vpu fusion proteins to prevent
CD4 cell surface expression was determined by transfection
in HeLa CD4+ cells followed by immunostaining of live
cells for surface CD4 prior to fixation. As shown in Fig. 7
and Table 1, transfection of HeLa CD4+ cells with a vector
expressing EGFP did not prevent CD4 surface expression
(Figs. 7A–C) while vectors expressing VpuSCEGFP1
prevented cell surface expression of CD4 (Figs. 7D–F).
Transfection of HeLa CD4+ cells with vectors expressing
VpuTAN1EGFP (Figs. 7G–I) and VpuGAB1EGFP (Figs. 7J–
L) proteins also prevented cell surface expression. Similar
results were obtained with vectors expressing VpuANTEGFP
and VpuCAM13EGFP (Table 1). As the results from the
immunofluorescence experiments indicated that SIVcpz Vpu
fusion proteins prevented CD4 cell surface expression, we
determined if the these proteins were capable of inducing
human CD4 degradation. 293 cells were co-transfected with
vectors expressing each of the SIVcpz Vpu fusion proteins
and the human CD4. As shown in Fig. 8A, co-transfection
with vectors expressing either VpuEGFP and human CD4
clearly resulted in degradation of human CD4, whereas the
expression of EGFP alone did not result in CD4 degrada-
tion. Co-transfection of vectors expressing CD4 and each of
the various SIVcpz Vpu fusion proteins also resulted in the
Fig. 5. Intracellular localization of EGFP, VpuEGFP, and VpuSCEGFP1. 293 cells were co-transfected with vectors expressing either EGFP and ECFP-Golgi
(Panels A–D), VpuEGFP and DSRed2-ER (Panels E–H), VpuEGFP and ECFP-Golgi (Panels I–L), VpuSCEGFP1 and ECFP-Golgi (Panels M–P) or
VpuSCEGFP1 and ECFP-Mem (Panels Q–T). At 48 h, cells expressing EGFP and ECFP were identified and analyzed by laser-scanning confocal microscopy
as described in Materials and methods. Panels A, E, I, M, and Q show EGFP or EGFP containing protein expression layered onto a phase contrast micrograph
of the field. Panels B, F, J, N, and R show expression of marker proteins layered onto a phase contrast micrograph of the field. Panels C, G, K, O, and S show
expression of the EGFP or EGFP fusion proteins and marker protein expression layered onto a phase contrast micrograph of the field. Panels D, H, L, P, and T
merges fluorescent micrographs of EGFP and marker protein expression.
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CD4 by the subtype B Vpu was inhibited in the presence of
proteasome inhibitors (Fujita et al., 1997), we tested
whether the proteasome inhibitor MG132 would preventVpu-mediated CD4 degradation by the SIVcpz Vpu fusion
proteins. 293 cells were co-transfected with vectors express-
ing CD4 and the various Vpu fusion proteins. At 48 h post-
transfection, cells were radiolabeled with 35S-methionine/
Fig. 6. Intracellular localization of VpuANTEGFP. 293 cells were co-transfected with vectors expressing the VpuANTEGFP and DsRed2-ER (Panels A–D),
VpuANTEGFP and ECFP-Golgi (Panels E–H), or VpuANTEGFP and ECFP-Mem (Panels I–L). At 48 h, cells expressing EGFP and ECFP or EGFP and
DsRed2 were identified and images were collected using laser scanning confocal microscopy as described in Materials and methods. Panels A, E, and I show
EGFP containing protein expression layered onto a phase contrast micrograph of the field. Panels B, F, and J show marker protein expression layered onto a
phase contrast micrograph of the field. Panels C, G, and K show EGFP and marker protein expression layered onto a phase contrast micrograph of the field.
Panels D, H, and L merge fluorescent micrographs of EGFP fusion proteins and marker protein expression.
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the presence of MG132. The results shown in Fig. 8C
indicate that MG132 prevented the HIV-1 subtype B and C
Vpu fusion protein-mediated degradation of CD4. Similar
results were obtained with the four SIVcpz Vpu fusion
proteins. Thus, both immunofluorescence and immunopre-
cipitation experiments indicated that all four SIVcpz Vpu
fusion proteins down-modulate CD4 and mediated CD4
degradation via the proteasome.
Disruption of the negatively charged domain carboxyl
terminal to the CK-II site of the SIVcpz ANT Vpu results in
a fusion protein that no longer prevents CD4 expression on
the cell surface
The SIVcpz ANT, CAM13, and TAN1 Vpu proteins have
a single potential casein kinase II (CK-II; S/T-X-X-E/D) site
(Fig. 1), yet previous studies on the HIV-1 subtype B Vpu
protein indicate that both sites are required for CD4 down-
regulation (Paul and Jabbar, 1997). Inspection of the
sequence revealed that the SIVcpz TAN1 and ANT Vpu
proteins have a stretch of 5 consecutive negatively charged
amino acids (see Fig. 1) just carboxyl to the CK-II site (andwhere the second CK-II is located in the subtype B and C
proteins). We determined whether these five consecutive
negatively charged amino acids could substitute for the lack
of a CK-II site. Using site-directed mutagenesis, we changed
the aspartic acid residue at position 61 to asparagine
[VpuANTEGFP(D61N)] or lysine [VpuANTEGFP(D61K)]
residues. An additional vector was constructed in which
the aspartic acid and glutamic acid residues at positions 61
and 63 were changed in ANT to positively charged lysine
residues [VpuANTEGFP(DE61,63KK)]. Transfection of
these constructs into HeLa CD4+ cells was analyzed for
CD4 expression (Table 1, Fig. 9). The results indicate that
VpuANT EGFP(D61N) and VpuANT EGFP(D61K) did not
prevent CD4 expression on the cell surface and this was also
true for the third mutant, VpuANTEGFP(DE61,63KK). In
addition, we also analyzed the ability of these mutants to
induce the degradation of human CD4. Co-transfection of
vectors expression human CD4 and VpuANTEGFP(D61N) or
VpuANTEGFP(DE61,63KK) failed to induce the degradation
of human CD4 (Fig. 10). Thus, these results indicated that an
intact negatively charged region carboxyl to the single CK-II
was required for the CD4 down-regulation by this SIVcpz
ANT Vpu.
Fig. 7. CD4 down-modulation by EGFP, VpuSCEGFP1, and SIVcpzVpuEGFP fusion proteins. HeLa CD4
+ cells, which express CD4, were transfected with
vectors expressing EGFP (Panels A–C), VpuSCEGFP1 (Panels D–F), VpuCAM13EGFP (Panels G–I), or VpuTAN1EGFP (Panels J–L). At 48 h post-
transfection, cells were stained for surface CD4 using a-CD4 antibody and a rhodamine conjugated secondary antibody followed by fixation with 1% formalin.
Cells were examined by laser scanning confocal microscopy. Panels A, D, G, and J. Cells examined using a filter to visualize CD4 expression and layered onto
a phase contrast image of the cell. Panels B, E, H, and K. Cells were examined using an appropriate filter to visualize identify cells expressing the EGFP or
EGFP fusion proteins. Panels C, F, I, and L. Merge of fluorescent micrographs with both filters (for expression of Vpu fusion protein and CD4 expression.
Panels A–C, cells transfected with a vector expressing EGFP. Panels D–F, cells transfected with a vector expressing VpuSCEGFP1. Panels G–I, cells
transfected with a vector expressing VpuCAM13EGFP. Panels J–L, cells transfected with a vector expressing VpuTAN1EGFP. Cells transfected with vectors
VpuCAM13EGFP and VpuANTEGFP showed CD4 down-regulation that was similar to the VpuGAB1EGFP and VpuTAN1EGFP (data not shown).
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the hinge region for CD4 down-regulation
The CAM13 Vpu protein also lacked a second con-
sensus CK-II site, but contained a second serine following
the first CK-II site. To determine if this serine was crucial
to the CD4 down-regulation, we changed this serine residue
to an alanine residue [VpuCAM13EGFP(S55A)]. Trans-
fection of the vector expressing this protein into HeLa
CD4+ cells clearly shows that this mutant did not prevent
human CD4 surface expression (Fig. 11, Table 1).
Similarly, co-transfection of 293 cells with vectors express-ing CD4 and VpuCAM13EGFP(S55A) did not result in CD4
degradation (data not shown). Together, these results
indicate that the second serine in the hinge region was
required for CD4 down-regulation and degradation by the
CAM13 Vpu protein.Discussion
In this study, we have analyzed four Vpu homologues
from SIVcpz for their intracellular transport properties and
the ability to down-regulate CD4. While these Vpu
Table 1
Results of CD4 surface expression following transfection with various
vectors expressing HIV-1, SIVcpz, and SIVcpz mutant fusion proteins
Protein expressed % cells positive
for EGFP
expression
HeLa CD4+ cells positive
for EGFP and surface
CD4 expression
VpuEGFP 9 ()
VpuSCEGFP1 14 ()
VpuANTEGFP 13 ()
VpuCAM13EGFP 10 ()
VpuGAB1EGFP 8 ()
VpuTAN1EGFP 11 ()
VpuANTEGFP(D61N) 10 (+)
VpuANTEGFP(D61K) 9 (+)
VpuANTEGFP(DE61,63KK) 14 (+)
VpuCAM13EGFP(S55A) 12 (+)
EGFP 22 (+)
aNumber of EGFP expressing HeLa CD4+ cells counted from three
experiments exceeded 400. Greater than 99% of the HeLa CD4+ cells were
positive for CD4 expression.
L.M. Gomez et al. / Virology 335 (2005) 46–60 53homologues are similar in length, they differ by up to
83% in their amino acid sequence from the HXB2 Vpu
protein. Additionally, three of the four SIVcpz Vpu
proteins contain a single potential CK-II site (defined
by the motif S/T-X-X-E/D with the serine or threonine
residues phosphorylated) while this region is highly
conserved in almost all Vpu proteins (McCormick-Davis
et al., 2000). Since phosphorylation of the two serine
residues in the two CK-II motifs was shown to be
necessary for the interaction of the HXB2 Vpu cyto-
plasmic domain with the CD4 molecule and is required
for the CD4 degradation (Paul and Jabbar, 1997;
Schubert and Strebel, 1994; Schubert et al., 1994), we
determined whether the lack of a second CK-II site
would alter SIVcpz Vpu function. Using a recently
developed EGFP reporter system (Pacyniak et al.,
2005; Singh et al., 2003), we found that all four SIVcpz
Vpu fusion proteins mediated CD4 degradation via the
proteasome and prevented cell surface expression of
CD4. Unlike a previous study that reported that the
subtype B Vpu protein required both consensus CK-II
sites for CD4 down-regulation (Paul and Jabbar, 1997),
our results indicated that the SIVcpz Vpu fusion proteins
did not require two consensus CK-II sites. Nonetheless,
two SIVcpz Vpu proteins containing a single consensus
CK-II site (ANT and TAN1) also contained a stretch of
negatively charged residues just carboxyl to the con-
sensus CK-II site. Phosphorylation at CK-II sites can in
some cases be substituted with negatively charged amino
acid residues, particularly aspartic acid residues (Firzlaff
et al., 1991; Hall et al., 1996). We speculated that the
negatively charged residues might be able to compensate
for the lack of a second CK-II site. This was indeed the
case as the introduction of uncharged or positively
charged amino acids into this region abrogated CD4
down-regulation. Thus, at least for the SIVcpz ANT Vpuprotein, negatively charged residues downstream of the
CK-II site were sufficient for the CD4 down-regulation
and degradation. This observation is consistent with
sequence of other SIV Vpu proteins. For example, the
predicted Vpu sequence of SIVmon has a stretch of six
negatively charged amino acids following the one
potential CK-II site and two Vpu sequences from SIVgsn
have a stretch of five consecutive negatively charged
amino acids in the region of the protein where the casein
kinase II sites normally reside. Whether these Vpu
proteins are capable of down-regulating cell surface
CD4 has not yet been reported.
The Vpu proteins from SIVcpz strains isolated from Pan
troglodytes troglodytes, CAM13 and GAB1, also down-
regulated CD4 expression. While the GAB1 sequence has
the two consensus CKII sites that are normally found in
HIV-1 Vpu proteins (McCormick-Davis et al., 2000), the
CAM13 has only one consensus CK-II site, but has a
second serine residue following the first CK-II site
(SGNESDGGEEEK with the CK-II site bolded). To
determine if this serine was essential to CD4 down-
regulation, we changed this second serine residue to an
alanine residue. The results demonstrated that this amino
acid substitution abrogated CD4 down-regulation. It is
possible that CK-II phosphorylates this serine even in the
absence of the consensus recognition sequence as it is
unlikely that the hydroxyl group (the difference between
serine and alanine) is responsible for the CD4 down-
regulating activity of the this protein. Whether this occurs
through the interaction with the h-TrCP protein, as has
been demonstrated for subtype B Vpu protein (Margottin
et al., 1998), or an alternative mechanism, remains to be
determined. However, the fact that the proteasome
inhibitor MG132 prevented SIVcpz Vpu-mediated degra-
dation, suggests a similar mechanism (Fujita et al., 1997;
Schubert et al., 1998). It is of interest that members of the
SIVcpz lineages appear to achieve CD4 down-regulation
by different mechanisms. Vpu proteins of SIVcpz strains
from P. t. schweinfurthii (ANT and TAN1) probably
utilize a negatively charged region following the single
consensus CK-II, whereas the two Vpu proteins from P. t.
troglodytes (CAM13 and GAB1) utilize phosphorylated
serine residues.
Studies on the subtype B Vpu protein have shown that
this protein is localized predominantly to the perinuclear
region (RER/Golgi complex) with little if any, transported
to the cell plasma membrane (Kimura et al., 1994;
Klimkait et al., 1990; Schubert et al., 1996a, 1996b;
Tiganos et al., 1998). Using this reporter system, we
showed that the subtype B Vpu fusion protein was
transported to same intracellular compartments previously
reported while Vpu fusion proteins generated with genes
from three primary HIV-1 subtype C Vpu EGFP fusion
proteins were transported to the cell plasma membrane
(Pacyniak et al., 2005). In this study, we also showed
that the carboxyl terminus of the well studied HXB2 Vpu
Fig. 8. The SIVcpz Vpu proteins induce degradation of human CD4 (Panel A) and the degradation is inhibited by the proteasome inhibitor MG132 (Panel B).
293 cells were transfected with vectors expressing human CD4 and either EGFP, VpuSCEGFP1, VpuANTEGFP VpuCAM13EGFP, VpuGAB1EGFP, or
VpuTAN1EGFP. At 48 h post-transfection, cells were starved for methionine and cysteine and radiolabeled with
35S-methionine/cysteine for 5 h. Cell lysates
were prepared in 1 RIPA buffer and the CD4 immunoprecipitated using a rabbit anti-human CD4 antibody and protein A Sepharose (PAS). The
immunoprecipitates were washed, boiled in sample reducing buffer and analyzed by SDS-PAGE (10% gel). Panel A, untreated cells. Lane 1, CD4 proteins
immunoprecipitated from cells transfected with vectors expressing human CD4 and EGFP. Lane 2, CD4 proteins immunoprecipitated from cells transfected
with vectors expressing human CD4 and VpuEGFP. Lane 3, CD4 proteins immunoprecipitated from cells transfected with vectors expressing human CD4 and
VpuANTEGFP. Lane 4, CD4 proteins immunoprecipitated from cells transfected with vectors expressing human CD4 and VpuCAM13EGFP. Lane 5, CD4
proteins immunoprecipitated from cells transfected with vectors expressing human CD4 and VpuGAB1EGFP. Lane 6, CD4 proteins immunoprecipitated from
cells transfected with vectors expressing human CD4 and VpuTAN1EGFP. Lane 7, CD4 protein immunoprecipitated from non-transfected cells. Panel B,
densiometric comparison of CD4 immunoprecipitated from co-transfection of 293 cells with vectors expressing CD4 and those expressing EGFP (control) or
Vpu fusion proteins. The values are the average of four experiments. Panel C, MG132-treated cells. Lane 1, CD4 proteins immunoprecipitated cells transfected
with the empty pcDNA3.1(+) vector (negative control). Lane 2, CD4 proteins immunoprecipitated from cells transfected with vectors expressing human CD4
and VpuEGFP. Lane 3, CD4 proteins immunoprecipitated from cells transfected with vectors expressing human CD4 and VpuANTEGFP. Lane 4, CD4 proteins
immunoprecipitated from cells transfected with vectors expressing human CD4 and VpuCAM13EGFP. Lane 5, CD4 proteins immunoprecipitated from cells
transfected with vectors expressing human CD4 and VpuGAB1EGFP. Lane 6, CD4 proteins immunoprecipitated from cells transfected with vectors expressing
human CD4 and VpuTAN1EGFP.
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resulted in retention in the Golgi complex (Pacyniak et
al., 2005). Our studies here showed that all four SIVcpz
fusion proteins, constructed in the same manner as the
HIV-1 subtype B and C Vpu fusion proteins, were alsotransported to the cell plasma membrane, or a total of
seven Vpu proteins that were transported to the cell
plasma membrane. To date, virtually all structure–
function studies have been formed using the Vpu proteins
from HXB2 and NL4-3 (which contains the vpu from the
Fig. 9. Down modulation of CD4 surface expression by VpuANTEGFP and mutant SIVcpz ANT Vpu fusion proteins. HeLa CD4
+ cells, which express CD4,
were transfected with vectors expressing VpuANTEGFP, VpuANTEGFP(D61N), VpuANTEGFP(D61K), or VpuANTEGFP(DE61,63KK). At 48 h post-
transfection, cells were stained for surface CD4 using anti-CD4 antibody and goat anti-mouse secondary antibody followed by fixation with 1% formalin. Cells
were examined by laser scanning confocal microscopy. Panels A, D, G, and J, cells examined using a rhodamine filter to visualize CD4 expression and layered
onto a phase contrast image of the cell. Panels B, E, H, and K, cells were examined using a fluorescein filter to identify cells expressing the Vpu fusion proteins.
Panels C, F, I, and L, fluorescent micrographs with dual filters (for expression of Vpu fusion protein and CD4 expression. Panels A–C, cells transfected with
the VpuANTEGFP. Panels D–F, cells transfected with VpuANTEGFP(D61N). Panels G–I, cells transfected with VpuANTEGFP(D61K). Panels J–L, Cells
transfected with VpuANTEGFP(DE61,63,KK).
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related to each other (McCormick-Davis et al., 2000) and
are derived from laboratory-adapted T cell tropic HIV-1 it
raises the question, ‘‘Is the predominant intracellular
localization of HXB2 an artefact of its laboratory
adaptation?’’ The intracellular localization of the HXB2
Vpu does not appear to be an artefact of fusion to EGFPas fusion of the HIV-1 subtype B and C Vpu proteins
and the SIVcpz ANT to another fluorescent protein
(HcRed1) also resulted in the same intracellular local-
ization (unpublished observations). This could be poten-
tially important as the other major function associated
with the Vpu protein is enhanced virion release from
cells. Since HIV-1 maturation in CD4+ T cells typically
Fig. 10. The SIVcpz ANT mutant Vpu proteins do not induce degradation of
human CD4. 293 cells were transfected with vectors expressing human
CD4 and either EGFP, VpuANTEGFP, VpuANTEGFP(D61N), and VpuANT
EGFP(D61,63K). At 48 h post-transfection, cells were starved for
methionine and cysteine and radiolabeled with 35S-methionine/cysteine
for 5 h. Cell lysates were prepared in 1 RIPA buffer and the CD4
immunoprecipitated using a rabbit anti-human CD4 antibody and protein A
Sepharose (PAS). The immunoprecipitates were washed, boiled in sample
reducing buffer, and analyzed by SDS-PAGE (10% gel). Lane 1, CD4
proteins immunoprecipitated from cells transfected with vectors expressing
human CD4 and EGFP. Lane 2, CD4 proteins immunoprecipitated from
cells transfected with vectors expressing human CD4 and VpuANT
EGFP(D61N). Lane 3, CD4 proteins immunoprecipitated ANT from cells
transfected with vectors expressing human CD4 and Vpu EGFP(D61,63K).
Lane 4, CD4 proteins immunoprecipitated from cells transfected with
vectors expressing human CD4 VpuANTEGFP. Lane 5, CD4 proteins
immunoprecipitated from non-transfected cells.
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members of the endosomal sorting complex required for
transport (ESCRT) I, II, and III complexes (Martin-
Serrano et al., 2003; Stuchell et al., 2004; von Schwedler
et al., 2003), studies with additional Vpu proteins from
clinical isolates may provide further information on the
potential interactions with these complexes.Fig. 11. The second serine within the hinge region of the VpuCAM13EGFP is requ
transfected with vectors expressing VpuCAM13EGFP (Panels A–D) VpuCAM13EG
surface CD4 using an anti-CD4 antibody and goat anti-mouse secondary antibod
examine by confocal microscopy. Panels A and E, cells examined using a fluores
image of the field. Panels B and F, cells were examined using a rhodamine filter
contrast image of the field. Panels C and G, EGFP and rhodamine images were la
micrographs of EGFP and rhodamine images to visualize expression of Vpu fusiMaterials and methods
Cells and vpu genes, and subcellular marker plasmids
293 cells were used for the transfection studies to assess
the intracellular localization of the fusion proteins and were
maintained in Dulbecco’s minimal essential medium
(DMEM), supplemented with 2 mM glutamine, 5 Ag per
ml gentamicin and 10% fetal bovine serum. HeLa CD4+
cells were used to assess CD4 down-modulation and were
maintained in DMEM supplemented with 2 mM glutamine,
5 Ag per ml gentamicin and 10% fetal bovine serum and 1
mg/ml Geneticin (G-418). For the studies reported here, we
used the vpu genes from four SIVcpz strains (ANT,
CAM13, GAB1, and TAN1) (Huet et al., 1990; Nerrienet
et al., 2004; Peeters et al., 1989, 1992; Santiago et al.,
2003a, 2003b; Vanden Haesevelde et al., 1996). The origin
of the SIVcpz viruses in this study is shown in Table 2. The
CAM13, TAN1 and ANT vpu genes were amplified
directly from fecal virion RNA and thus these vpu genes
were derived from samples without prior passage in culture.
Subcellular marker plasmids pDsRed2-ER (catalog number
632409), pECFP-Golgi (catalog number 632357) and
pECFP-Mem (catalog number 632360) were obtained from
Clontech (Palo Alto, Ca). The vpu genes used for the
construction of the subtype B and C Vpu proteins were the
HXB2 (with a corrected initiation codon) and the C-
96BW16B01 isolates, respectively. Unlike the HXB2 Vpu
which is derived from a T cell line adapted HIV-1 isolate,ired for CD4 down-regulation. HeLa CD4+ cells, which express CD4, were
FP(S55A) (Panels E–H). At 48 h post-transfection, cells were stained for
y followed by fixation with 1% formalin. Cover slips were mounted and
cein filter to visualize EGFP expression and layered onto a phase contrast
to identify cells expressing the cell surface CD4 and layered onto a phase
yered onto phase contrast images of the field. Panels D and H, fluorescent
on protein and CD4.
Table 2
SIVcpz Vpu proteins analyzed
SIVcpz strain Chimpanzee Status
at ID
Year
of IDa
Age
at IDa
Sex Country subspeciesb Current
Status
Source of Vpu
gene
Reference
SIVcpz CAM13 CAM13 Wild-born 2001 <2 M Cameroon P.t.t. Deceased,
2002
Fecal viral RNA (Nerrienet et al., 2005)
SIVcpz GAB1 GAB1 Wild-born 1987 >2 F Gabon P.t.t. Deceased,
1990
Molecular clone
from phage library
generated from
co-culture of GAB1
PBMC and SW480
cells
(Huet et al., 1990;
Peeters et al., 1989)
SIVcpz ANT Ch-No Wild-born 1987 >2 M DRC P.t.s. Alive Fecal viral RNA (Peeters et al., 1992)
SIVcpz TAN1 Ch-06 Wild-living 2000 23 M Tanzania P.t.s. Alive Fecal viral RNA (Santiago et al., 2003a,
2003b)
Abbreviations: ID = identification; M = male, F = female.
a This refers to the year/age of rescue for captive wild-born chimpanzees, or the year/age of positive identification for wild-living chimpanzees.
b Subspecies was determined by mtDNA d-loop analysis. P.t.t. = Pan troglodytes troglodytes, P.t.s. = P. t. schweinfurthii.
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PBMCs without passage in culture (Novitsky et al., 1999).
The amino acid sequence of the Vpu proteins analyzed in
this study is shown in Fig. 1.
Phylogenetic analysis
Concatenated amino acid sequences spanning the Vif-
Vpr-Vpu region (370 amino acids consensus length) of
representative HIV-1 and SIVcpz strains were aligned using
CLUSTAL W (Thompson et al., 1994). Gaps in any of the
sequences or ambiguous areas were excluded from all
comparisons. Phylogenies were inferred by neighbor-joining
method (Saitou and Nei, 1987) and subjected to bootstrap
analysis with 1000 subreplicates.
The subtype B and C Vpu fusion proteins and the
construction of the plasmids expressing the VpuANTEGFP,
VpuCAM13EGFP, VpuGAB1EGFP, and VpuTAN1EGFP fusion
proteins
The construction of vectors expressing the subtype B and
subtype C Vpu proteins fused to the SC gene of enhanced
green fluorescent protein (VpuEGFP and Vpu EGFP1,
respectively) have been described (Pacyniak et al., 2005;
Singh et al., 2003). The expressed VpuEFGP was localized
predominantly to the Golgi complex and prevented cell
surface expression of CD4 (Singh et al., 2003). The
VpuSCEGFP1 was found to be expressed at the cell surface
(Pacyniak et al., 2005). Thus, the VpuEGFP and the
VpuSCEGFP1 were used to compare the intracellular
expression of the SIVcpz ANT fusion proteins. For the
construction of the SIVcpz VpuEFGP chimeric proteins
(VpuANTEGFP, VpuCAM13EGFP, and VpuGAB1EGFP, and
VpuTAN1EGFP), a similar strategy was used consisting of:
(1) amplification of the vpu gene with the restriction
endonuclease NcoI sites at either end of the gene; (2)
cloning the amplified product into the pGEMT-Easy vector;
(3) digestion of the pGEMT-Easy vector containing the Vpuinsert with NcoI and subcloning into the NcoI site of the
pEGFP vector (Clontech); (4) sequencing the insert for
correct orientation in the pEGFP vector; and (5) digestion of
the pEGFP vector containing the fused VpuEFGP genes
with KpnI and StuI and subcloning into the pcDNA3.1 (+)
that was digested with KpnI and EcoRV.
Transfection and intracellular localization studies
VpuEGFP and other fusion proteins were transfected into
human 293 cells to assess their subcellular localization using
a cationic polymer (polyethylenimine) transfection reagent
(ExGeni 500, MBI Fermentas) using the manufacturer’s
protocol. Briefly, 1–3 105 cells were seeded into each well
of 6 well tissue culture plate 24 h prior to transfection.
Transfection was carried out on cultures that were 50–60%
confluent using 4.75 Ag plasmid DNA and 15.5 Al of
ExGeni 500 corresponding to 6 equivalents. Each plasmid
DNA samples and polyethylenimine were diluted in 300 Al
of 150 mM sodium chloride solution separately. Samples
were vortexed gently and immediately centrifuged at low
speed for few seconds. Polyethylenimine was then added to
the plasmid DNA solution, mixed with a vortex and allowed
to stand at room temperature for 10 min. The 293 cells were
washed with serum-free media twice and added with 3.0 ml
of DMEM. Polyethylenimine/DNAmixture was added to the
cells and the plate swirled by slow hand rotation for couple
of seconds. Culture plates were centrifuged at 280  g for 5
min and incubated at 37 -C for 30 min. The medium from
transfected cultures was replaced with fresh complete
growth media and cells were incubated at 37 -C in 5%
CO2 atmosphere. For confocal microscopy, 293 cells were
plated onto cover slips. To prepare cells for detection of
EGFP fluorescence, the medium was removed after 48 h
following transfection, the monolayers on cover slips were
briefly rinsed in PBS and the cells fixed for 10 min at room
temperature in freshly prepared 1% paraformaldehyde in
PBS. The fixed cells on cover slips were mounted on slides
(Prolong Anti-Fade (Molecular Probes, Eugene, OR).
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Scanning Microscope, LSM-510 using an excitation wave-
length of 488 nm with a LP-505 emission filter. Images
were analyzed and 3-dimensional reconstructions of the
subcellular localization of the VpuEGFP mutants were
generated using LSM-510 software.
To examine the intracellular localization of the SIVcpz
Vpu fusion proteins, co-transfection studies were performed
using pDsRed2-ER, pECFP-Golgi and pECFP-Mem vectors
(Clontech). 293 cells were co-transfected with vectors
expressing one of the Vpu fusion proteins and either
DsRed- ER, ECFP-Golgi or ECFP-Mem as described
above. Cells expressing both proteins (i.e., the VpuEGFP
and either ECFP protein or DsRed2-ER) were identified.
Fluorescent digital images were obtained using a Zeiss
LSM510 confocal microscope equipped with an Argon/2
laser (25 mW) for the excitation (488 nm, 50% laser power)
and detection (band pass 505–530 nm filter; BP505–530)
for EGFP, excitation (458 nm, 100% laser power) and
detection (band pass 475–525 nm filter; BP475–525) for
ECFP, and excitation (558 nm, 100% laser power) and
detection (band pass 588 nm filter: BP560) for DsRed2.
Images were acquired in Multitrack channel mode (sequen-
tial excitation/emission) with LSM510 (v 3.2) software and
a Plan-Apochromat 100X/1.4 Oil DIC objective with frame
size of 2048  2048 pixels. Detector gain was set initially to
cover the full range of all the samples and background
corrected by setting the amplifier gain, and all images were
then collected under the same photomultiplier detector
conditions and pinhole diameter.
Immunoprecipitation analyses
For radiolabeling studies, 293 cells were transfected as
described above and at 48 h after transfection, the medium
was removed and transfected cells were incubated in
methionine/cysteine-free Dulbecco’s modified Eagle’s me-
dium (DMEM) for 2 h. The cells were radiolabeled for 5 h
with 500 ACi of 35S-Translabel (methionine and cysteine,
MP Biomedical, Costa Mesa, CA). EGFP containing
proteins were immunoprecipitated from the cell lysates
using an a-EGFP antibody and protein A Sepharose (PAS).
Immunoprecipitates collected on PAS were washed three
times, boiled in sample reducing buffer, and analyzed by
SDS-PAGE (10% gel) (Pacyniak et al., 2005; Singh et al.,
2003). Proteins were then visualized by standard autoradio-
graphic techniques.
Isolation of P100 and S100 fractions
For membrane enrichment studies, 293 cells were trans-
fected with vectors expressing either pcEGFP, pcvpuEGFP
or the SIVcpz Vpu fusion proteins. At 48 h, cells were
washed three times with phosphate-buffered saline (PBS;
pH 7.4) and then placed in a hypotonic solution consisting
of 10 mM Tris–HCl, pH 7.4, 1 mM CaCl2 and 1 mMMgCl2. The cells were disrupted by homogenization in a
tight fitting Potter–Elevjhem homogenizer and nuclei
removed by spinning at 1000  g for 10 min. The
supernatant was removed and saved. The pellet (containing
nuclei) was washed and pelleted an additional two times and
the supernatants pooled. The supernatants were then
subjected to centrifugation at 100,000  g (Beckman
SW55Ti rotor, 32,000 rpm) for 30 min. The supernatant
fraction and the pellet containing membranes were col-
lected. The membrane enriched pellet was resuspended in
1 RIPA buffer and the supernatant fraction made 1 with
respect to RIPA buffer. EGFP containing proteins were
immunoprecipitated using an a-EGFP serum and (PAS) as
described above. In other experiments, the P100 fraction
was resuspended in phosphate-buffered saline (PBS, pH
7.4) containing 0.5% Triton X-100 and then centrifuged at
100,000  g for 30 min. The pellet and supernatant
fractions were then subjected to immunoprecipitation
analysis as described above using the a-EGFP serum.
Assays for CD4 surface expression and degradation
HeLa CD4+ cells were grown on cover slips and
transfected with pcvpuEGFP as described earlier. At 48 h
post-transfection, cells were washed twice with wash
buffer (PBS pH 7.2, containing 2% fetal calf serum and
0.01% NaN3) and reacted with mouse anti-CD4 (clone
SFCI12T4D11CD4, Beckman-Coulter, 1:50 dilution) for
45 min. After the incubation, cover slips were washed
three times and incubated with rhodamine-conjugated
secondary antibody (goat antimouse, Chemicon, 1:50
dilution) for 35 min followed by washing five times in
buffer without serum. Cells were then fixed in 1%
formalin for 10 min, washed twice, equilibrated with
antifade buffer, and mounted on microscope glass slides
using Anti-fade (Molecular Probes). Cells were immedi-
ately observed by laser scanning confocal microscopy
using appropriate filters to visualize the EGFP containing
proteins and visualization of CD4 staining. All the staining
procedures were performed on ice and in the dark. HeLa
CD4+ cells transfected with a vector expressing EGFP
alone (pcEGFP) served as control for down-regulation of
CD4 and cultures of HeLa CD4+ cells treated with wash
buffer instead of primary antibody served as a negative
control for CD4 staining. A minimum of 400 EGFP
expressing cells were analyzed per construct.
In addition to detection of CD4 on the cell surface of
transfected HeLa CD4+ cells, co-transfection experiments
were performed using vectors expressing each VpuEGFP
fusion protein and a vector expressing the human CD4
protein (pCMV4Neo; Goldsmith et al., 1995). Cells were
transfected with Vpu fusion and pCMV4Neo vectors at a 3:1
ratio to insure that all cells transfected with the CD4
expressing vector were also transfected with the vector
expressing the Vpu fusion proteins. At 48 h post-transfection,
cells were starved for methionine/cysteine and then radio-
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radiolabel was removed and replaced with medium con-
taining cold excess methionine/cysteine for 5 h. In some
experiments, cells were treated with the proteasome
inhibitor MG132 (50 AM) during the radiolabeling and
chase periods. Cells were lysed in RIPA buffer, lysates
prepared, and the CD4 immunoprecipitated using a rabbit
anti-CD4 (sc-7219; Santa Cruz Biotechnology) and PAS.
Immunoprecipitates were collected, washed three times with
1 RIPA and analyzed by SDS-PAGE (10% gel). Controls
included co-transfection with pcEGFP (expressing on
EGFP) as negative control and co-transfection with a
pcvpuEGFP or pcvpuSCEGFP1 (expressing the subtype B
and C Vpu) as a positive controls.
Site-directed mutagenesis of SIVcpz ANT and SIVcpzCAM13
vpu genes
Site-directed mutagenesis was performed using comple-
mentary oligonucleotides (only sense oligonucleotide
shown) and the Quick-Change Mutagenesis Kit (Stratagene)
according to the manufacturer’s instructions. Three site-
directed mutations were introduced into SIVcpz ANT vpu
using oligonucleotide primers (sense strand shown) 5V-
GCAATAGAAGAAAATGAGGAAGCCAAT-3V to change
an aspartic acid residue at position 61 to an asparagine residue
[VpuANTEGFP(D61N)]; oligonucleotide primer 5V-GCAA-
TAGAAGAAAAGGAGGAAGCCAAT-3V to change the
asparagine to a lysine residue [VpuANTEGFP(D61K)]; and
oligonucleotide primer 5V-GAAGAAAAGGAGAAAGC-
CAATACATAT-3V to change the glutamic acid at position
63 to a lysine [VpuANTEGFP(DE61,63KK)]. Similarly,
oligonucleotide 5V-ATAGTGGAAATGAAGCCGATGGA-
GGAGAGG-3V was used to change the serine residue at
position 55 in the SIVcpzCAM13 vpu gene to an alanine
residue [VpuCAM13EGFP(S55A)]. Sequence changes were
confirmed by sequence analysis and the mutant vpu genes
inserted into the pcDNA3.1(+) vector for expression studies.Acknowledgments
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